A New Zealand company is at the forefront of stem cell research.
There are predictions the global market will reach nearly US$15 billion by next year.
ReGen Cellular musculoskeletal specialist Zaid Matti told Mike Yardley 50 per cent of those who suffer from arthritis are of a working age.
He says stem cells are a good alternative to having an operation, which can keep you away from work for weeks.
"You can actually come in, get your treatment, go back to work. A lot of my patients go back to work the same day."